Efficacy of the use of the synbiotic Maxibalance in the complex therapy of the small intestine bacterial overgrowth syndrome in patients with irritable bowel syndrome with diarrhea

Abstract

Aim. To evaluate the effectiveness of Maxibalance in the complex therapy of the small intestine bacterial overgrowth syndrome (SIBOS) in patients with irritable bowel syndrome (IBS) with diarrhea using a hydrogen breath test with glucose.
 Materials and methods. 66 patients with PCOS with diarrhea were examined, 30 patients made up the control group. The diagnosis of PCOS was determined according to the Rome IV criteria (2016). The diagnosis of SNBR was confirmed using the hydrogen breath test (HBT) with glucose. Medical treatment of patients in both groups included the use of antispasmodics, rifaximin. To the patients of the first group, the synbiotic Maxibalance was added to the treatment. Outpatient observation of patients lasted 8 weeks.
 The results. After the end of the course of treatment, 4 weeks (1 month) later, the patients underwent a repeated VDT with glucose in order to control the effectiveness of the treatment, which showed a negative result of SNBR in 77% of patients. Patients also reported a significant improvement in the condition and reduction of IBS symptoms after a course of treatment with the addition of the synbiotic Maxibalance to the therapy.
 Conclusions. The data obtained from the study indicate that the small intestine bacterial overgrowth syndrome is present in more than half of patients diagnosed with IBS with diarrhea, and therefore it should be suspected in this category of patients. The use of complex therapy of SIBOS in patients with IBS with diarrhea, including non-absorbable broad-spectrum antibiotics such as rifaximin and probiotics Maxibalance is a safe and effective approach to the treatment of IBD, helps to normalize and reduce symptoms of heart failure in patients with IBS with diarrhea and improving well-being.